Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MIST Stock Forecast 2026-2027
$2.01
Current Price
$236.51M
Market Cap
Buy 4
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to MIST Price Targets
+298.0%
To High Target of $8.00
+298.0%
To Median Target of $8.00
-0.5%
To Low Target of $2.00
MIST Price Momentum
+45.7%
1 Week Change
+12.9%
1 Month Change
+168.0%
1 Year Change
-0.5%
Year-to-Date Change
-34.3%
From 52W High of $3.06
+219.0%
From 52W Low of $0.63
📊 TOP ANALYST CALLS
Did MIST Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Milestone is one of their latest high-conviction picks.
Latest MIST Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, MIST has a bullish consensus with a median price target of $8.00 (ranging from $2.00 to $8.00). The overall analyst rating is Strong Buy (8.8/10). Currently trading at $2.01, the median forecast implies a 298.0% upside. This outlook is supported by 4 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Brandon Folkes at HC Wainwright & Co., projecting a 298.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MIST Analyst Ratings
4
Buy
1
Hold
0
Sell
MIST Price Target Range
Low
$2.00
Average
$8.00
High
$8.00
Current: $2.01
Latest MIST Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MIST.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 6, 2026 | HC Wainwright & Co. | Brandon Folkes | Buy | Reiterates | $8.00 |
| Dec 16, 2025 | Wells Fargo | Mohit Bansal | Overweight | Maintains | $8.00 |
| Dec 15, 2025 | HC Wainwright & Co. | Brandon Folkes | Buy | Maintains | $8.00 |
| Dec 15, 2025 | TD Cowen | Ritu Baral | Buy | Upgrade | $8.00 |
| Sep 11, 2025 | Wells Fargo | Mohit Bansal | Overweight | Initiates | $4.00 |
| Jun 5, 2025 | HC Wainwright & Co. | Brandon Folkes | Buy | Assumes | $5.00 |
| Apr 1, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Maintains | $10.00 |
| Mar 28, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $25.00 |
| Mar 17, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $25.00 |
| Feb 28, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $25.00 |
| Jan 27, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $25.00 |
| Oct 14, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $25.00 |
| Aug 22, 2024 | Rodman & Renshaw | Brandon Folkes | Buy | Initiates | $9.00 |
| Aug 22, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $25.00 |
| Jul 1, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $25.00 |
| May 30, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $25.00 |
| May 16, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $25.00 |
| Mar 22, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $25.00 |
| Mar 5, 2024 | Piper Sandler | Edward Tenthoff | Overweight | Maintains | $5.00 |
| Feb 26, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $25.00 |
Milestone Pharmaceuticals Inc. (MIST) Competitors
The following stocks are similar to Milestone based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Milestone Pharmaceuticals Inc. (MIST) Financial Data
Valuation Metrics
Market Cap
$236.51M
Enterprise Value
$-18,367,994
P/E Ratio
N/A
PEG Ratio
-1.8x
Price/Sales
135.5x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
-1,116.2%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+321.2%
Current Ratio
8.0x
Debt/Equity
139.8x
ROE
-229.7%
ROA
-41.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Milestone Pharmaceuticals Inc. (MIST) Business Model
About Milestone Pharmaceuticals Inc.
What They Do
Develops treatments for cardiovascular conditions.
Business Model
Milestone Pharmaceuticals generates revenue primarily through the commercialization of its lead product, etripamil, a nasal spray for treating paroxysmal supraventricular tachycardia (PSVT). The company focuses on efficient R&D spending to bring innovative treatments to market, with plans to expand etripamil's applications to other cardiovascular issues such as atrial fibrillation.
Additional Information
Founded in 2003 and headquartered in Montreal, Canada, Milestone boasts a leadership team with extensive experience in the pharmaceutical industry, particularly in cardiovascular medicine and drug development, positioning the company to effectively navigate regulatory processes and market challenges.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
38
CEO
Mr. Joseph G. Oliveto M.B.A.
Country
Canada
IPO Year
N/A
Website
www.milestonepharma.comMilestone Pharmaceuticals Inc. (MIST) Latest News & Analysis
Latest News
Quick Summary
A registry study design was presented at the Preventive Cardiovascular Nurses Association's 2026 Cardiovascular Nursing Symposium.
Why It Matters
The presentation of a registry study design may signal advancements in cardiovascular treatment, influencing investor sentiment in health care and biotech sectors focused on cardiovascular innovations.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
3 days ago
Quick Summary
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) will present at the 25th Annual Needham Virtual Healthcare Conference from April 13-16, 2026, focusing on cardiovascular medicines.
Why It Matters
Milestone Pharmaceuticals' presentation at a major healthcare conference could attract investor interest, potentially impacting stock performance and market sentiment in the biopharmaceutical sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Milestone Pharmaceuticals Inc. granted 123,000 stock options under its 2021 Inducement Plan to attract three new employees, as approved by its Compensation Committee and Board.
Why It Matters
The grant of equity awards indicates Milestone Pharmaceuticals' commitment to attracting talent, which can enhance innovation and growth, potentially impacting future stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Milestone Pharmaceuticals announced that Express Scripts has added its CARDAMYST™ (etripamil) nasal spray to its national formularies, effective March 27, 2026.
Why It Matters
The addition of CARDAMYST™ to Express Scripts' formularies expands its market access, potentially boosting sales and revenue for Milestone Pharmaceuticals, positively impacting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Milestone Pharmaceuticals Inc. (MIST) held its Q4 2025 earnings call, discussing financial performance and future outlook. Specific details from the call were not provided.
Why It Matters
Milestone Pharmaceuticals' Q4 2025 earnings call may reveal financial performance, growth prospects, and strategic plans, influencing stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Milestone Pharmaceuticals (Nasdaq: MIST) reported Q4 and full-year 2025 results, highlighting FDA approval and launch of CARDAMYST™ for treating PSVT in adults.
Why It Matters
Milestone Pharmaceuticals' FDA approval and product launch of CARDAMYST™ can significantly boost revenue and market position, influencing stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About MIST Stock
What is Milestone Pharmaceuticals Inc.'s (MIST) stock forecast for 2026?
Based on our analysis of 8 Wall Street analysts, Milestone Pharmaceuticals Inc. (MIST) has a median price target of $8.00. The highest price target is $8.00 and the lowest is $2.00.
Is MIST stock a good investment in 2026?
According to current analyst ratings, MIST has 4 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.01. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MIST stock?
Wall Street analysts predict MIST stock could reach $8.00 in the next 12 months. This represents a 298.0% increase from the current price of $2.01. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Milestone Pharmaceuticals Inc.'s business model?
Milestone Pharmaceuticals generates revenue primarily through the commercialization of its lead product, etripamil, a nasal spray for treating paroxysmal supraventricular tachycardia (PSVT). The company focuses on efficient R&D spending to bring innovative treatments to market, with plans to expand etripamil's applications to other cardiovascular issues such as atrial fibrillation.
What is the highest forecasted price for MIST Milestone Pharmaceuticals Inc.?
The highest price target for MIST is $8.00 from Brandon Folkes at HC Wainwright & Co., which represents a 298.0% increase from the current price of $2.01.
What is the lowest forecasted price for MIST Milestone Pharmaceuticals Inc.?
The lowest price target for MIST is $2.00 from at , which represents a -0.5% decrease from the current price of $2.01.
What is the overall MIST consensus from analysts for Milestone Pharmaceuticals Inc.?
The overall analyst consensus for MIST is bullish. Out of 8 Wall Street analysts, 4 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $8.00.
How accurate are MIST stock price projections?
Stock price projections, including those for Milestone Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 10, 2026 1:13 PM UTC